Advancing immune checkpoint inhibitor rechallenge: key insights into efficacy, safety, and personalized strategies in advanced solid tumors

ICI rechallenge benefits the right patients significantly. We propose a clinical decision model that might assist in integrating both biological and clinical variables to base individualized rechallenge, but the standard set of criteria and possibilities to validate biomarkers remains in urgent need.